Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment

CONCLUSION: Our results suggest a favourable anatomical and visual response after treatment switch to brolucizumab in patients with nAMD refractory to previous anti-VEGF agents.PMID:37461836 | DOI:10.1177/11206721231187663

Source: European Journal of Ophthalmology - July 18, 2023 Category: Opthalmology Authors: Argyrios Chronopoulos Elisa Huynh Agharza Ashurov James S Schutz Jost B Jonas Lars-Olof Hattenbach Source Type: research